SagripantiA., BarsottiG.Bleeding and thrombosis in chronic uremia.Nephron1997; 75: 125–39.
2.
KimK.J., YangW.S., KimS.B., LeeS.K., ParkJ.S.Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin.Perit Dial Int1997; 17: 157–61.
KimS.B., LeeS.K., ParkJ.S., ChiH.S., HongC.D., YangW.S.Effects of fixed low-dose warfarin on hemostatic factors in CAPD patients.Am J Kidney Dis2001; 37: 343–7.
5.
HaaberA.B., EidemakI., JensenT., Feldt–RasmussenB., StrandgaardS.Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure.J Am Soc Nephrol1995; 5: 1581–4.
6.
BlannA.D., MaxwellS.R.J., BurrowsG., MillerJ.P.Antioxidants, von Willebrand factor and endothelial cell injury in hypercholesterolaemia and vascular disease.Atherosclerosis1995; 116: 191–8.
7.
JanssonJ.H., NilssonT.K., JohnsonO.von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction.Br Heart J1991; 66: 351–5.
8.
WimanB., AnderssonT., HallqvistJ., ReuterwallC., AhlbomA., FaireU.Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.Arterioscler Thromb Vasc Biol2000; 20: 2019–23.
9.
BlannA.D., JacksonP., BathP.M.W., WattsG.F.Von Willebrand factor, a possible indicator of endothelial cell damage, decreases during long-term compliance with a lipid-lowering diet.J Intern Med1995; 237: 557–61.
10.
HeimbürgerO., StenvinkelP., BerglundL., TranæusA., LindholmB.Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.Nephron1996; 72: 135–44.
